- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: Whooping cough vaccine may not prevent infection
- Chickenpox vaccine does not appear to increase incidence of shingles, study finds
- At least 23,000 die from antibiotic-resistant infections each year, CDC finds
MISSISSAUGA, Ontario — Canadian drug maker Valeant Pharmaceuticals International will acquire rights to topical drugs for eczema and cold sores from Swedish drug maker Meda.
Valeant said it would buy rights for the eczema drug Elidel (pimecrolimus) and the cold sore drug Xerese (acyclovir and hydrocortisone) for the United States, Canada and Mexico. Valeant said, however, that Xerese has not yet received regulatory approval in Canada.
Valeant will pay Meda $76 million upfront and over the next 18 months will pay a series of potential milestone payments and royalties of about $130 million.